Navigation Links
Sanofi Pasteur Presents Positive Results of Tetravalent Dengue Candidate Vaccine
Date:11/6/2007

LYON, France, November 6 /PRNewswire-FirstCall/ -- Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced today positive results in the development of a vaccine for the global prevention of dengue fever, one of the most widespread tropical diseases. The results are being presented today at the American Society of Tropical Medicine and Hygiene (ASTMH)'s 56th annual meeting held in Philadelphia, Pennsylvania, USA.

These results have prompted Sanofi Pasteur to immediately expand ongoing clinical trials in Asia and Latin America. Submission to health authorities for registration is anticipated in 2012.

"Sanofi Pasteur made research for a vaccine against dengue fever one of its top priorities by investing in the most promising technology and dedicating top scientists to this lifesaving project," said Wayne Pisano, President and Chief Executive Officer of Sanofi Pasteur. "Sanofi Pasteur's goal is to make dengue fever a vaccine-preventable disease as quickly as possible with a vaccine available to people living in endemic countries or traveling to tropical destinations."

Immunization with Sanofi Pasteur's tetravalent dengue candidate vaccine generated a sero-neutralizing antibody response against all four serotypes of the virus responsible for dengue fever in 100 percent of adults who participated in a trial in the United States.(1)

"Developing a dengue vaccine has been a major challenge for over a decade, and we are very pleased with the breakthrough progress made by Sanofi Pasteur with its tetravalent dengue vaccine," said Harold Margolis, MD, Director of the Pediatric Dengue Vaccine Initiative (PDVI). "We believe this moves the world closer to a dengue vaccine that will be available for people who most need it."

Dengue fever is a mosquito-borne disease affecting up to 100 million people each year and resulting in 24,000 deaths, mostly among children, according to estimates from the World Health Organization (WHO).(2
'/>"/>

SOURCE Sanofi Pasteur
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Sanofi-Aventis renews licenses for Genomatix chip analysis pipeline
2. Sanofi-aventis US Chairman Tim Rothwell Addresses CMSAs Collaborative Practice Summit
3. Sanofi Pasteur and Institut Pasteur Team up Against Malaria
4. Sanofi-aventis Announces a Good Third Quarter Performance; Increase in 2007 full-year earnings growth guidance
5. Updated GOLD report presents new understandings in diagnosis, treatment and prevention of COPD
6. The Art Of Maternity(TM) at Destination Maternity(R) Presents A Sacred Passage Into Motherhood; the Art of Belly Masking to Belly Casting
7. Presentation Time Correction: Keryx Biopharmaceuticals Presents at 12:00pm, ET Tomorrow (Oct. 3) at William Blair & Company Small-Cap Growth Stock Conference
8. VNUS Medical Technologies Presents at William Blair Small-Cap Growth Stock Conference
9. NARSAD - Worlds Leading Mental Health Research Charity - Presents 19th Annual New York Mental Health Symposium, Oct. 19th & 20th
10. Retirement Living TV Presents Sex, Drugs and Rock N Roll
11. AviaraDx Presents at 2007 BIOCOM Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2009)NEW ORLEANS, Dec. 5 Leukemia and myeloproliferative disorders are serious and often deadly blood cancers. Research presented today at the 51st Annual Meeting of the American Society of Hematology int
(Date:12/5/2009)The MAMA campaign is a collaborative effort by the National Association of Certified Professional Midwives (NACPM), Midwives Alliance of North America (MANA), Citizens for Midwifery (CfM), Internation
(Date:12/4/2009)SAN FRANCISCO, Dec. 4 Medithrive, Inc. has won the Patient,s Choice Award as the favorite dispensary in the SF Bay Area by popular vote conducted by the online website, www.weedmaps.com. Despite on
(Date:12/4/2009)MADISON HEIGHTS, Mich., Dec. 4 The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Allergan, Inc. (NYSE: AGN ) as its February 2010 "Stock to Stud
(Date:12/4/2009)STANFORD, Calif. A new study shows that muscle cells grown in the lab can restore an intestine,s ability to squeeze shut properly. The work, performed in dogs and rats, might ultimately help treat pa
Breaking Medicine News(10 mins):Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 2Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 3Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 4Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 5Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 6Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 7Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 8Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 9Health News:AquaNatal Birth Center Gives Away a Waterbirth Package to Celebrate the Successful MAMA Campaign 2Health News:AquaNatal Birth Center Gives Away a Waterbirth Package to Celebrate the Successful MAMA Campaign 3Health News:AquaNatal Birth Center Gives Away a Waterbirth Package to Celebrate the Successful MAMA Campaign 4Health News:BetterInvesting Magazine Releases February Stock to Study and Undervalued Stock Choicesfor Investors' Informational and Educational Use 2Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 2Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 3Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 4
...vide Market-Leading Dental Tools and Services to ...NAPOLIS, April 29 WellPoint, Inc. (NYSE:,WLP), th...announced the,acquisition of DeCare Dental, one of...roup customers. The acquisition of,DeCare enhances...
...ril 29 Hundreds of,bicyclists are expected to par...e-day fundraising ride starting in Newton, Massach...is July 18-20. The event and its,participants rais...mmer, the Trek is distributing cowbells in the,com...
... LAUNCHES, FREDERICK, Md., April 29 BioElectroni...ew website, http://www.actipatch.it ,is now selli...SS Medical,(Tecnica Scientifica Service), designed...uartered in Torino, Italy. Over,10,000 ActiPatch u...
...pril 29 In conjunction,with DURECT Corporation,s ...lts press release, you are invited to listen to th... the Internet on Wednesday, May 7th, 2008,at 4:30 ... by accessing,DURECT,s homepage at http://www.dur...
...50 had agreement on standard outcomes, review find...- Few studies consider the appropriate measurement...hildren, say University of Liverpool researchers w...ldren in the process to select which measurements ...
...may now be predicted more realistically according ...rnal of Clinical Endocrinology & Metabolism (JCEM)...MH) levels are related to the onset of menopause a... small follicles present in a womans ovaries. This...
Other Medicine News:Health News:WellPoint Announces Acquisition of DeCare Dental 2Health News:WellPoint Announces Acquisition of DeCare Dental 3Health News:WellPoint Announces Acquisition of DeCare Dental 4Health News:WellPoint Announces Acquisition of DeCare Dental 5Health News:More Cowbell! To end ALS, Riders of the Tri-State Trek Cycle 270 Miles - Making Noise and Raising Money! 2Health News:More Cowbell! To end ALS, Riders of the Tri-State Trek Cycle 270 Miles - Making Noise and Raising Money! 3Health News:BioElectronics Corporation Announces New Website for Italian Market 2Health News:BioElectronics Corporation Announces New Website for Italian Market 3Health News:Measurements Poor for Assessing Clinical Trials With Children 2
(Date:12/3/2009)DOYLESTOWN, Pa., Dec. 3 Ted Karkus, Chairman and CEO of The Quigley Corporation, (Nasdaq: QGLY ) www.quigleyco.com announced today that the Company has completed its evaluation of its opportunitie
(Date:12/3/2009)WILMINGTON, Del., Dec. 3 ParagonRx, a Delaware-based company specializing in pharmaceutical risk management and optimal medication use, will host a free webinar on Wednesday, Dec. 9, on the FDA,s dra
(Date:12/3/2009)DURHAM, N.C., Dec. 3 In response to the increasingly critical role of healthcare information technologies in the evolving healthcare delivery system, Duke Medicine has created the Duke Center for Hea
Breaking Medicine Technology:Quigley CEO, Ted Karkus, Announces Phase One of 2010 Strategic Plan; Karkus Reports that the Primary Focus will be on Leveraging its OTC Platform; Company Aggressively Seeking Product Acquisitions and Line Extensions which Leverage its Distribution 2Quigley CEO, Ted Karkus, Announces Phase One of 2010 Strategic Plan; Karkus Reports that the Primary Focus will be on Leveraging its OTC Platform; Company Aggressively Seeking Product Acquisitions and Line Extensions which Leverage its Distribution 3Duke Medicine to Train Healthcare Professionals in Health Informatics 2Duke Medicine to Train Healthcare Professionals in Health Informatics 3New test for safer biomedical research results 53248 1New test for safer biomedical research results 53248 2Sun exposure may trigger certain autoimmune diseases in women 53245 1Sun exposure may trigger certain autoimmune diseases in women 53245 2Got zinc 3F New zinc research suggests novel therapeutic targets 9433 1Got zinc 3F New zinc research suggests novel therapeutic targets 9433 2
...tion at 24 Months, SAN DIEGO, Dec. 12 Ceregene, ... a Phase 1 clinical trial of CERE-120 in 12,patien...s gene therapy to,deliver the neural growth factor...that occurs in the brains of Parkinson,s disease,p... 24 months post,treatment, suggest a sustained red...
... Inc., a,biotechnology company developing orally a...at the Company has initiated a multi-dose trial wi...ent for smallpox infection. This,trial will study ...the drug,given to healthy volunteers., "The high ...ase I trial,has validated the utility of the compa...
Other Medicine Technology:Ceregene Presents Long-term Follow-up From Phase 1 Trial of CERE-120 in Parkinson's Disease 2Ceregene Presents Long-term Follow-up From Phase 1 Trial of CERE-120 in Parkinson's Disease 3Ceregene Presents Long-term Follow-up From Phase 1 Trial of CERE-120 in Parkinson's Disease 4Chimerix Initiates a Multi-dose Clinical Trial of the Company's Lead Compound, CMX001, for the Treatment for Smallpox Infection 2
...ratory and a worldwide leader in innovative labora...nsive test menu of highly complex and unique medic... by the University of Utah, ARUP Laboratories' cli...sity teaching hospitals and children's hospitals, ...
...ratory and a worldwide leader in innovative labora...nsive test menu of highly complex and unique medic... by the University of Utah, ARUP Laboratories' cli...sity teaching hospitals and children's hospitals, ...
...ratory and a worldwide leader in innovative labora...nsive test menu of highly complex and unique medic... by the University of Utah, ARUP Laboratories' cli...sity teaching hospitals and children's hospitals, ...
...ratory and a worldwide leader in innovative labora...nsive test menu of highly complex and unique medic... by the University of Utah, ARUP Laboratories' cli...sity teaching hospitals and children's hospitals, ...
Medicine Products: